Agoracom Blog Home

Posts Tagged ‘CSE’

« Older Entries
Newer Entries »

Twitch’s New Virtual Currency Stream+ Could Be A Boost For Esports Betting $GMBL

Posted by AGORACOM-JC at 9:04 AM on Thursday, October 6th, 2016

Breakaway includes the option to make bets using the new virtual currency, Stream+.

During a brief video demonstration of Breakaway, Amazon Game Studios showed that players could wager on matches and earn Steam+ coins by watching.

Adam Wong, managing editor for Double Helix, part of Amazon Game Studios, explained:

“We wanted to create more ways for viewers, broadcasters and players to interact with each other on Twitch, so various teams within Amazon Game Studios are building new features that enhance the experience between players, broadcasters and viewers.”

Patrick Gilmore of Amazon Game Studios gave only slightly more information on Stream+:

“Stream+ is a loyalty points system where players can earn points by watching streams.”

He added that Stream+ points could be spent on wagering, but exactly how the system will work, and whether the Stream+ points or coins would be tradable across or outside of the Twitch platform was left unaddressed.

Game currencies raise regulatory issues

The issue is important from a regulatory point of view. The UK Gambling Commission (UKGC) has made its position clear.

If a virtual currency or in-game article (a skin) can be monetised, then it is the equivalent of money. If used for an activity that qualifies as gambling, then the provider needs a gambling licence.

“Where ‘skins’ are traded or are tradeable and can therefore act as a de facto virtual currency and facilities for gambling with those items are being offered, we consider that a licence is required.”

Twitch will almost certainly avoid skin betting controversy

The last few months have seen Valve attempt to stop its Steam platform being used for skin betting. Almost all the betting has revolved around CS:GO skins, which could be traded and monetized on third party sites.

Valve’s approach to the regulatory and reputational risks that arose will have been taken on-board by Twitch.

The likelihood is that Twitch will make certain that any gambling using Stream+ will fit strictly within the confines of the legal definitions of social gaming.

This will not prevent Twitch or game producers from receiving revenues from the sale of Stream+ coins, but will mean that Twitch is likely to set ground rules preventing the coins from subsequently being monetized.

Esports Betting Industry Coverage Brought To You By Betway

Esports betting may see second order benefits

While the new currency may not see esports betting operators benefit directly, it may introduce more players and fans to the fun of betting on their favorite players and games.

This greater awareness that betting is possible reduces the gap which esports betting operators have to bridge in attracting customers.

If customers are accustomed to betting on in-game action in Breakaway, betting real money on a Dota 2 or League of Legends tournament will be less of a novelty.

Source: http://www.esportsbettingreport.com/twitch-introduces-new-virtual-currency/

Tags: , , , , , , ,
Posted in eSports Investing, VGambling Inc. | Comments Off on Twitch’s New Virtual Currency Stream+ Could Be A Boost For Esports Betting $GMBL

Namaste Announces Non-Brokered Private Placement of Units $N.ca

Posted by AGORACOM-JC at 8:10 AM on Wednesday, October 5th, 2016

Namastelarge_copy

  • Non-brokered private placement financing of units of the Company (“Units”) at a price of $0.12 per Unit, with each Unit being comprised of one common share of the Company (a “Common Share”) and one-half of one common share purchase warrant
  • Each full Warrant being exercisable for one Common Share at an exercise price of $0.20 per Common Share for a period of 24 months

VANCOUVER, BRITISH COLUMBIA–(Oct. 5, 2016) – Namaste Technologies Inc. (“Namaste” or “Company”) (CSE:N)(CSE:N.CN)(FRANKFURT:M5BQ) announces a non-brokered private placement financing of units of the Company (“Units”) at a price of $0.12 per Unit, with each Unit being comprised of one common share of the Company (a “Common Share”) and one-half of one common share purchase warrant (a “Warrant”), with each full Warrant being exercisable for one Common Share at an exercise price of $0.20 per Common Share for a period of 24 months (the “Offering”).

The Offering will consist of up to 16.67 million Units issued for total gross proceeds of $2,000,000. The proceeds of the Offering will be used to fund the acquisition of certain assets of URT1 Limited and its subsidiaries (including wind down and restructuring charges), inventory expansion, commercialization of new products and general corporate purposes. The proceeds will be released to the Company concurrently with the closing of the Offering which is expected to occur on or about October 13, 2016.

Closing of the Offering is subject to the following:

  • Receipt of all necessary regulatory approvals, including without limitation, CSE approval if required; and
  • Execution and delivery of standard documentation containing typical representations and warranties, covenants, conditions and other provisions.

All securities issued in connection with the Offering are subject to a four month and a day hold period. Finder’s will be paid a cash fee equal to 7% of the gross proceeds raised in the Offering. In addition, Finder’s will receive broker warrants (“Broker Warrants”) exercisable for Units equal in number to 7% of the number of Units sold under the Offering. The Broker Warrants will be exercisable at a price of $0.12 per Unit for a period of 24 months after the closing of the Offering.

About Namaste Technologies Inc.

Namaste Technologies Inc. is an emerging leader in vaporizer and accessories space. Namaste has 26 ecommerce retail stores in 20 countries, offers the largest range of brand name vaporizers products on the market and is actively manufacturing and launching multiple unique proprietary products for retail and wholesale distribution. The Company is currently focused on expanding its product offering, acquisitions and strategic partnerships, and entering new markets globally.

On behalf of the Board of Directors

Sean Dollinger, Chief Executive Officer

Further information on the Company and its products can be accessed through the link below:

www.namastetechnologies.com

www.namastevaporizers.com

www.namastevaporizers.co.uk

www.vaporseller.com

FORWARD LOOKING INFORMATION This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors 5 discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The CSE has neither reviewed nor approved the contents of this press release.

Namaste Technologies Inc.
Sean Dollinger
Chief Executive Officer
Direct: +1 (786) 389 9771
[email protected]
www.namastetechnologies.com

 

Tags: , , , , ,
Posted in Namaste Technologies Inc. | Comments Off on Namaste Announces Non-Brokered Private Placement of Units $N.ca

VIDEO: Cannabix Technologies Marijuana Breathalyzer Is Already In Demand, Says Former RCMP Officer $BLO.ca

Posted by AGORACOM-JC at 4:01 PM on Tuesday, October 4th, 2016

If you’re looking to invest in the small cap medical marijuana space, then Cannabix Technologies has to be high on your research list.  Why?  Anticipated legalization across the USA and Canada is obviously going to lead to higher use … which is going to automatically increase the need for monitoring right through the roof.

Specifically, police departments and the courts are going to need a way to both detect and convict impaired drivers.  The same goes for hazardous and dangerous jobs that require employees and heavy equipment operators to be anything but impaired.  Unfortunately, traditional saliva and urine tests simply can’t cut it.  The world will need a detection device that is fast, accurate and can hold up in a court of law.

Cannabix Technologies is in the process of bringing its marijuana breathalyzer to market.  With the underlying technology under license from the University of Florida and with the device in development as we speak, demand has already inundated Cannabix according to its President, Kal Malhi. The Company is in the final stages of completing its “Beta 2.0” device and expects to have a pilot test ready device for scientific trials for later this fall. The trial testing would be conducted to prove the accuracy and sensitivity of the Cannabix Breathalyzer, and the results would be used to apply for a court accepted device certification by the Minister of Justice in Canada and the National Highway and Traffic Safety Authority in the U.S.

Rule #1 when investing in small caps is make sure the company is run by smart people.  Kal Malhi is a former RCMP officer, where he completed his duties in the drug enforcement and organized crime divisions. He’s not only smart, he’s also been in the fight. Add on the fact he is the President of BullRun Capital and you have the prototype of Small Cap 2.0, the next generation of Canadian small cap companies that will be built for the long term, not to flip 5 cent paper.  Kal is the real deal.

BullRun has raising capital for various projects totaling in excess of $100 million dollars since 2008. Kal has specialized in working with academia, advances in technology and funded academic research that has potential for commercialization thru private and public companies.

Cannabix Technologies has the strong potential of creating both great shareholder value and societal benefits for years to come. I personally consider their product critically needed technology to keep our roads and families safe given the marijuana legislative easing that is taking place around North America.

Watch the interview and do your DD. As I’ve said before, we are officially in Weed 2.0 where you can bet on the long term development of real marijuana companies for decades to come. Just as Web 2.0 dwarfed the original dot-com bubble, Weed 2.0 is going to dwarf the original marijuana bubble. Do your research and make your investments.

Hub On AGORACOM / Corporate Website / Watch Interview

Tags: , ,
Posted in All Recent Posts, Cannabix Technologies Inc., Medical Marijuana Stocks | Comments Off on VIDEO: Cannabix Technologies Marijuana Breathalyzer Is Already In Demand, Says Former RCMP Officer $BLO.ca

Cannabix Technologies is Well-Positioned to Capitalize on Anticipated Marijuana Legalization in Canada and United States $BLO.ca

Posted by AGORACOM-JC at 10:27 AM on Tuesday, October 4th, 2016

Logo_773

  • Later this fall, voters in California, Arizona, Nevada, Maine and Massachusetts will decide whether marijuana should be legalized for recreational use
  • Cannabix Technologies Inc. is developing a point of care device that would be similar to alcohol breathalyzers and would be used at the roadside to collect evidence of marijuana impairment
  • This tool would also be useful in testing employees for on the job sobriety

VANCOUVER, BRITISH COLUMBIA–(Oct. 4, 2016) – Cannabix Technologies Inc. (CSE:BLO) (CSE:BLO.CN) (OTC PINK:BLOZF) (the “Company”) Later this fall, voters in California, Arizona, Nevada, Maine and Massachusetts will decide whether marijuana should be legalized for recreational use. The Canadian Liberal government also recently announced plans to introduce legislation legalizing marijuana in the spring of 2017. The Canadian government has set up a Task Force on Marijuana Legalization and Regulation, chaired by the Honourable Anne McLellan and spearheaded by Mr. Bill Blair, MP, current Parliamentary Secretary to the Minister of Justice, to consult with experts across the country to learn how to best legalize and regulate marijuana.

More recently in Canada, the Liberal government has just wrapped up a several month feedback program asking Canadians about their opinions on marijuana legalization and how the government should enforce laws against those who operate outside the legal limits, such as marijuana impaired driving.

With the pending legalization of marijuana, law enforcement agencies across North America and the world are grappling with the issue of marijuana impaired driving. Law enforcement has done a commendable job in enforcing alcohol impaired driving in North America and society has also come to frown on alcohol impaired driving. Alcohol impaired driving is enforced with sophisticated breathalyzers that collect evidence of impairment and criminal charges have a high likelihood of resulting in conviction.

Unlike alcohol impaired driving, society is still unsure of how to address marijuana impaired driving and many jurisdictions and law enforcement agencies are trying to determine how best to administer the issue of “drugged driving”.

In addition to marijuana impaired driving, employers are also concerned with employees that may be impaired by marijuana. These workplace issues could be particularly concerning when heavy machinery is involved and safety is paramount.

Cannabix Technologies Inc. is developing a point of care device that would be similar to alcohol breathalyzers and would be used at the roadside to collect evidence of marijuana impairment. This tool would also be useful in testing employees for on the job sobriety.

Cannabix Technologies‘ Marijuana Breathalyzer

Cannabix Technologies has been a first mover and leader in the development of a marijuana breathalyzer. The company debuted its most recent beta prototype in July. With a Field Asymmetric Ion Mobility Spectrometry (FAIMS) mass spec setup, the company is developing a tool that would be capable of accurately detecting THC concentrations at levels found in breath samples.

Cannabix Technologies‘ breathalyzer would determine whether someone has consumed THC within the two hours preceding the test. This test would be unlike saliva or urine testing which can result in positive tests days after consumption of THC. The Cannabix Breathalyzer would consequently provide a critical measure of “recency” to avoid implicating drivers that are no longer high.

Cannabix is in the final stages of completing its “Beta 2.0” device and expects to have a pilot test ready device for scientific trials for later this fall. The trial testing would be conducted to prove the accuracy and sensitivity of the Cannabix Breathalyzer, and the results would be used to apply for a court accepted device certification by the Minister of Justice in Canada and the National Highway and Traffic Safety Authority in the U.S.

Mr. Kal Malhi, President of Cannabix, stated, “Our generation is in the midst of a monumental shift in the legislation and societal views on marijuana use. Like the economic opportunity that alcohol legalization provided in the last century, impending marijuana legalization is providing an immense economic opportunity for investors in the marijuana sector.”

We seek Safe Harbor.

On behalf of the Board of Directors

– Kal Malhi, President, Cannabix Technologies Inc.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking information that involves various risks and uncertainties regarding future events. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company, such as final development of a commercial or prototype product(s), successful trial or pilot of company technologies, no assurance that commercial sales of any kind actually materialize; no assurance the Company will have sufficient funds to complete product development. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including: (i) adverse market conditions; (ii) risks regarding protection of proprietary technology; (iii) the ability of the Company to complete financings; (v) the ability of the Company to develop and market its future product; and (vi) risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that the marijuana breathalyzer business will provide any benefit to the Company, and no assurance that any proposed new products will be built or proceed. There is no assurance that existing “patent pending” technologies licensed by the Company will receive patent status by regulatory authorities. The Company is not currently selling commercial breathalyzers. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.

Cannabix Technologies Inc.
(604) 551-7831
604-676-2767
[email protected]
www.cannabixtechnologies.com

Tags: , , ,
Posted in All Recent Posts, Cannabix Technologies Inc., Medical Marijuana Stocks | Comments Off on Cannabix Technologies is Well-Positioned to Capitalize on Anticipated Marijuana Legalization in Canada and United States $BLO.ca

Namaste Announces New Partnerships With Sneaky Pete and VaporTownUSA $N.ca

Posted by AGORACOM-JC at 8:43 AM on Tuesday, October 4th, 2016

Namastelarge_copy

  • Entered into two new strategic partnerships to expand its market presence as the leading e-commerce company focused on vaporizers and accessories
  • Partnerships are with well-known online reviewer Sneaky Pete (SPV Enterprises LLC) and VaporTownUSA.com
  • Partnerships are anticpated to enhance the overall revenue of Namaste through online video reviews, high quality links to the Namaste sites and expansion of sales channels internationally

VANCOUVER, BRITISH COLUMBIA–(Oct. 4, 2016) – Namaste Technologies Inc. (“Namaste” or “Company) (CSE:N)(FRANKFURT:M5BQ) is pleased to report that it has entered into two new strategic partnerships to expand its market presence as the leading e-commerce company focused on vaporizers and accessories. The partnerships are with well-known online reviewer Sneaky Pete (SPV Enterprises LLC) and VaporTownUSA.com. Both these partnerships are anticpated to enhance the overall revenue of Namaste through online video reviews, high quality links to the Namaste sites and expansion of sales channels internationally. Additional information can be accessed on each of the entities at www.sneakypetestore.com and www.vaportownusa.com.

Sneaky Pete is a leading source of information for cannabis consumers that has generated hundreds of thousands of YouTube views. Sneaky Pete’s professional quality reviews focus on the latest vaporizer products and are often a first place of reference for product consumers. Sneaky Pete’s videos drive traffic to Sneaky Pete’s online store as well as affiliate traffic to Namaste. Under this new partnership, Namaste will manage all credit card processing, logistics and inventory fulfillment. SPV Enterprises will be compensated based on Namaste’s drop shipping price platform. Namaste has already begun the integration of Sneaky Pete’s online store and expects a live launch on or about October 10, 2016. Namaste will utilize its e-commerce resources to enhance video rankings and conversion rates for Sneaky Pete’s Youtube channel and retail store.

VaporTownUSA.com is an existing online retail site for vaporizers and accessories. Namaste will be managing sales, customer service and logistics for VaportownUSA.com and net profits will be shared between VaporTownUSA.com management and Namaste equally. Through this relationship, Namaste plans to expand VaporTownUSA’s product offering and increase sales by utilizing search engine optimization and inbound marketing techniques. VaporTownUSA generated approximately C$200,000 of revenues in 2015

Management Commentary

Mr. Sean Dollinger, President and CEO of Namaste, comments: “These new partnerships with Sneaky Pete and VaporTownUSA represent our company’s strategy to build and nurture strategic relationships within our industry through exposure to new sales channels and growth through online retail consolidation. We have always been strong supporters of Sneaky Pete and are very proud to have him on as a part of our team. Likewise, the partnership and integration of VaporTownUSA represents another aspect of our strategy in operating existing retail sites. Namaste continues to pursue multiple additional partnerships of this nature.”

About Namaste Technologies Inc.

Namaste Technologies Inc. is an emerging leader in vaporizer and accessories space. Namaste has 26 ecommerce retail stores in 20 countries, offers the largest range of brand name vaporizers products on the market and is actively manufacturing and launching multiple unique proprietary products for retail and wholesale distribution. The Company is currently focused on expanding its product offering, acquisitions and strategic partnerships, and entering new markets globally.

On behalf of the Board of Directors

Sean Dollinger, Chief Executive Officer

Further information on the company and its products can be accessed through the link below:

www.namastetechnologies.com

www.namastevaporizers.com

www.namastevaporizers.co.uk

www.vaporseller.com

FORWARD-LOOKING INFORMATION

This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions. Namaste assumes no responsibility to update or revise forward looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors 5 discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The CSE has neither reviewed nor approved the contents of this press release.

Namaste Technologies Inc.
Sean Dollinger
+ 1 (786) 389-9771
[email protected]
www.namastetechnologies.com

 

Tags: , , , , ,
Posted in All Recent Posts, Namaste Technologies Inc. | Comments Off on Namaste Announces New Partnerships With Sneaky Pete and VaporTownUSA $N.ca

Tetra Bio-Pharma Inc. Announces Its Pre-IND Meeting with FDA was Granted $TBP.ca

Posted by AGORACOM-JC at 8:35 AM on Tuesday, October 4th, 2016

Growpros_hub_large

  • Received a PRE-IND Acknowledgement and Meeting Request Granted letter from the US FDA
  • Submitted a request for a Type B pre-IND meeting with the USA Food and Drug Administration (FDA) for its PPP001 dried cannabis drug product
  • Meeting will be held in late January 2017 with the Division of Anesthesia, Analgesia, and Addiction Products (DAAAP), Center for Drug Evaluation and Research (CDER)

OTTAWA, ONTARIO–(Oct. 4, 2016) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (CSE:TBP)(CSE:TBP.CN), through its subsidiary, PhytoPain Pharma Inc. (“PPP“), a pharmaceutical company focused on developing and commercializing therapeutic cannabis-based products for the treatment of pain and other medical conditions announces that it received a PRE-IND Acknowledgement and Meeting Request Granted letter from the US FDA.

According to Dr. G. Chamberland, Chief Scientific Officer, PPP submitted a request for a Type B pre-IND meeting with the USA Food and Drug Administration (FDA) for its PPP001 dried cannabis drug product. The meeting will be held in late January 2017 with the Division of Anesthesia, Analgesia, and Addiction Products (DAAAP), Center for Drug Evaluation and Research (CDER).

Dr. Chamberland further commented that the Company intends on submitting a Clinical Trial Application later this year and, if authorized by Health Canada, would initiate its Phase I trial in humans later this year. He added, “The timing of the meeting with the FDA is perfect as it will allow the corporation time to adjust its clinical development program if the Orphan Drug Indications are granted. The first clinical trial of PPP001 will be performed in healthy volunteers and provide the Company with a good understanding of the pharmacokinetics and safety of the drug product. This will then allow the Company to subsequently proceed to perform clinical studies in patient populations based on an acceptable benefit-to-risk ratio for human subjects”.

The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Dr. Guy Chamberland
Chief Scientific Officer
514-220-9225

Tetra Bio-Pharma Inc.
Andre Audet
Executive Chairman
613-421-8402

Tetra Bio-Pharma Inc.
Ryan Brown
President, Grow Pros MMP
613-421-8402

Tags: , ,
Posted in Medical Marijuana Stocks, Tetra Bio-Pharma Inc., Tetra Brio-Pharma Inc. | Comments Off on Tetra Bio-Pharma Inc. Announces Its Pre-IND Meeting with FDA was Granted $TBP.ca

Tetra Bio-Pharma Inc. Announces that its Phase I Trial of Inhaled Marijuana in Healthy Volunteers Will Be Performed by Algorithme Pharma, an Altasciences Company $TBP.ca

Posted by AGORACOM-JC at 8:36 AM on Thursday, September 29th, 2016

Growpros_hub_large

  • Selected Algorithme Pharma, an Altasciences company, for the conduct of its Phase I clinical trial in healthy human subjects
  • Using the services of Algorithme Pharma based on its experience and expertise in the conduct of clinical trials for the pharmaceutical industry

OTTAWA, ONTARIO–(Sept. 29, 2016) – Tetra Brio-Pharma Inc. (“Tetra” or the “Company“) (CSE:TBP)(CSE:TBP.CN), through its wholly-owned subsidiary, PhytoPain Pharma Inc. (“PPP“), a pharmaceutical company focused on developing and commercializing therapeutic cannabis-based products for the treatment of pain and other medical conditions, has selected Algorithme Pharma, an Altasciences company, for the conduct of its Phase I clinical trial in healthy human subjects. PPP is using the services of Algorithme Pharma based on its experience and expertise in the conduct of clinical trials for the pharmaceutical industry.

According to Dr. G. Chamberland, Chief Scientific Officer, “Adequately evaluating the safety of inhaled marijuana requires well-equipped clinical research facilities and investigational teams experienced in handling the administration of investigational drugs by inhalation to human volunteers. A fully assembled medical device, PPP001-titanium pipe, will be used for combustion of the marijuana and subsequent inhalation of the generated smoke.”

“We are proud to have been selected by PPP for their Phase I trial. We have partnered closely with PPP to design a unique Phase I trial in healthy human subjects to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple daily ascending doses of the company’s PPP001 inhalation marijuana investigational drug product.” explained Dr. Graham Wood, Executive Vice President, Phase I Clinical Development, at Algorithme Pharma.

Dr. Chamberland further commented that this regulatory filing is part of PPP’s dedication to the commercialization of marijuana as a prescription controlled drug and the Company’s plan to seek reimbursement by insurers for patients. He added that this Phase I trial will only begin after approval of the Clinical Trial Application (CTA) by the Therapeutic Products Directorate, Health Canada, Research Ethics Board approval, and obtaining an exemption from the Office of Controlled Substances for the conduct of the study.

About Altasciences

Altasciences Clinical Research encompasses Algorithme Pharma and Vince & Associates Clinical Research, making it one of the largest early phase clinical CROs in North America. With over 25 years’ experience, Altasciences provides clinical development services to biopharmaceutical companies worldwide, including study conduct, medical writing, biostatistics, data management, and bioanalysis.

The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Dr. Guy Chamberland
Chief Scientific Officer
514-220-9225

Andre Audet
Executive Chairman
613-421-8402

Ryan Brown
President, Grow Pros MMP
613-421-8402

Tags: , ,
Posted in Medical Marijuana Stocks, Tetra Bio-Pharma Inc., Tetra Brio-Pharma Inc. | Comments Off on Tetra Bio-Pharma Inc. Announces that its Phase I Trial of Inhaled Marijuana in Healthy Volunteers Will Be Performed by Algorithme Pharma, an Altasciences Company $TBP.ca

Mining Commisioner Issues Final Order in Cliffs Bid for Easement Over KWG Railroad Claims $KWG.ca

Posted by AGORACOM-JC at 2:46 PM on Tuesday, September 27th, 2016

Kwglarge

  • Advises that the Mining and Lands Commission of Ontario has made a final Order that the “Pending Proceedings” notation be removed from the abstracts of the Mining Claims
  • Final Order also provided that no costs shall be paid by any party to the application.
  • Final Order follows the Supreme Court of Canada’s (“SCC”) dismissal of Canada Chrome Corporation’s application for leave to appeal the decision of Ontario’s Court of Appeal

TORONTO, ONTARIO–(Sept. 27, 2016) – KWG Resources Inc. (CSE:KWG)(FRANKFURT:KW6) (“KWG”) advises that the Mining and Lands Commission of Ontario has made a final Order that the “Pending Proceedings” notation be removed from the abstracts of the Mining Claims of KWG subsidiary Canada Chrome Corporation, that the time during which they were the subject of pending proceedings be excluded, and that a new anniversary date for the filing of prescribed assessment work be established.

The final Order also provided that no costs shall be paid by any party to the application.

The final Order follows the Supreme Court of Canada’s (“SCC”) dismissal of Canada Chrome Corporation’s application for leave to appeal the decision of Ontario’s Court of Appeal. The following citation was published on September 4th:

2274659 Ontario Inc. v. Canada Chrome Corporation, 2016 ONCA 145 (36973) Canada Chrome staked more than two hundred mining claims along the 340-kilometre corridor of high ground [south]ward from its deposit to Exton, Ontario. Canada Chrome wanted to build a railway along that corridor and drilled boreholes for that purpose. When a partner in [the] deposit decided to pursue a different deposit, it approached the Ministry of Natural Resources for easements allowing the construction of a road from that deposit to Nakina, Ontario. The requested easements passed directly over the boreholes drilled by Canada Chrome for its rail lines. When Canada Chrome refused consent to the easements, the Minister referred the application to the Commissioner under s. 51(2) of the Mining Act. The Commissioner dismissed the application. The Divisional Court allowed an appeal from that decision (decision of Commissioner set aside; application to dispense with Respondent’s consent granted). The C.A. dismissed the appeal. C.A.: appeal dismissed. “The application for leave to appeal . . . is dismissed without costs.”

“This means that an application to the Ontario Ministry of Natural Resources which was made by Cliffs Natural Resources in early 2012, for the grant of an easement over the claims of Canada Chrome Corporation, may now proceed,” said KWG President Frank Smeenk. “In the decision of the Divisional Court of Ontario issued July 30th, 2014 Madam Justice Swinton wrote ‘the issue being decided under s. 51(4) of the Mining Act does not deprive CCC of its ability at the next stage to oppose Cliffs’ easement application or to ask for conditions that would protect its legitimate interests in its mining claims.’ However there is no indication that the easement application will be continued.

“At the time of the Divisional Court decision the possibility of CCC building a railroad to transport ore over its claims from the Ring of Fire was dismissed. We believe that our engagement of China Railway First Survey & Design Institute Group Company Ltd. to complete a Bankable Feasibility Study substantially overcomes that incredulity.

“It is unfortunate that our exploration industry has generally come to believe that the Court decisions in this contest mean that anyone can use our ‘railroad claims’ for their own competing purpose. We had hoped that the Supreme Court of Canada might address that kind of issue by reviewing the decision of the Ontario Court of Appeal and confirming the ‘finders-keepers’ nature of mining claims staking in doing so. As that was not to be, we are pleased that this gratuitous attack on our company’s assets has now been exhausted and dissipated!”

About KWG:

KWG has a 30% interest in the Big Daddy chromite deposit and the right to earn 80% of the Black Horse chromite where resources are being defined. KWG also owns 100% of CCC which has staked claims and conducted a surveying and soil testing program, originally for the engineering and construction of a railroad to the Ring of Fire from Aroland, Ontario. KWG subsequently acquired intellectual property interests, including a method for the direct reduction of chromite to metalized iron and chrome using natural gas. KWG subsidiary Muketi Metallurgical LP is prosecuting two chromite-refining patent applications in Canada, China, India, Indonesia, Japan, Kazakhstan, South Africa, South Korea, Turkey, and USA. The filings have been receipted in each of those jurisdictions.

Shares issued and outstanding: 961,320,281

KWG Resources Inc.
Bruce Hodgman
Vice-President
416-642-3575
[email protected]

Tags: , , , , ,
Posted in KWG Resources | Comments Off on Mining Commisioner Issues Final Order in Cliffs Bid for Easement Over KWG Railroad Claims $KWG.ca

Demand For Esports Content Prompts Sky And ITV To Make $4 Million Ginx TV Investment $GMBL

Posted by AGORACOM-JC at 3:30 PM on Monday, September 26th, 2016
satellite dishes on rooftop

The demand for televised esports content is about as new a new thing as could be, but UK broadcasters ITV and Sky TV are determined to get ahead of the game.

Sky and ITV are doubling down on their initial investment in Ginx TV, which went live in June this year. Each has invested £1.55 million ($2 million) in cash and payment in kind via the provision of broadcasting services for a 16.5 percent stake in Ginx TV.

Ginx says that it is already to distributed to 14 million homes in the UK and Ireland and its foreign distribution takes the channel into another 23 million homes, letting Ginx claim to be the “largest eSports TV channel in the world, reaching 37 million homes.”

Emma Lloyd, group director of business development and strategic partnerships at Sky, commented:

“We’re really excited to have followed up our commercial partnership with Ginx with this investment, which will help us deepen our understanding of eSports and its audience. At Sky we are committed to bringing new programmes and channels such as GINX eSports TV to support and extend our leadership position in content.”

ITV and Sky have options to increase their stake further

The regulatory news announcement put out by ITV stated that:

“Both ITV and Sky have the option to acquire further holdings in Ginx TV. If either party does not take up its option, the remaining party may have the option to acquire 100%.”

Ginx is a 24/7 broadcaster offering a schedule that covers major esports tournaments such as FACEIT’s eSports Championship Series, and Valve’s The International Dota 2. It also offers independent programming, and rebroadcasts the Turner Broadcasting ELEAGUE.

Esports fans get to watch at times that are convenient to them, and the brand reputation of ITV and Sky help to create mainstream respectability for the content.

That 24/7 coverage also makes Ginx a critical resource and promoter for online esports betting.

TV coverage and esports betting can be expected to feed off each other as each expands. The consequent growth of Ginx may make the Sky and ITV options potentially very valuable.

Source: http://www.esportsbettingreport.com/sky-itv-invest-ginx-esports-tv/

Tags: , , ,
Posted in All Recent Posts, eSports Investing, VGambling Inc. | Comments Off on Demand For Esports Content Prompts Sky And ITV To Make $4 Million Ginx TV Investment $GMBL

Medical Marijuana Seems To Reduce Deaths From Pharmaceuticals $MCOA.us $GCI.ca

Posted by AGORACOM-JC at 4:47 PM on Thursday, September 22nd, 2016
  • Columbia University epidemiologist June Kim and her colleagues report that fatally injured drivers are less likely to test positive for opioids in states that allow medical use of marijuana
  • That finding, together with the results of earlier studies, indicates that making marijuana legally available to patients saves lives by reducing their consumption of more dangerous medications.

BY: Jacob Sullum , Contributor

I cover the war on drugs from a conscientious objector’s perspective.

Opinions expressed by Forbes Contributors are their own.

Marijuana jars at the West Coast Collective, a dispensary in Los Angeles (Image: Frederic J. Brown/AFP/Getty Images)

Insys Therapeutics, the Arizona-based pharmaceutical company that recently became the biggest financial supporter of the campaign against marijuana legalization in that state, makes an oral spray that delivers the opioid painkiller fentanyl and plans to market another one that contains dronabinol, a synthetic version of THC. Insys says it gave $500,000 to the main group opposing Arizona’s legalization initiative because the measure “fails to protect the safety of Arizona’s citizens, and particularly its children.” But one needn’t be terribly cynical to surmise that Insys also worries about the impact that legalization might have on its bottom line, since marijuana could compete with its products.

A new study suggests Insys has good reason to worry. In an article published last week by the American Journal of Public Health, Columbia University epidemiologist June Kim and her colleagues report that fatally injured drivers are less likely to test positive for opioids in states that allow medical use of marijuana. That finding, together with the results of earlier studies, indicates that making marijuana legally available to patients saves lives by reducing their consumption of more dangerous medications.

Kim et al. collected data from the Fatality Analysis Reporting System (FARS) for 1999 through 2013, focusing on 18 states that drug-tested at least 80% of drivers who died in crashes. They found that drivers between the ages of 21 and 40 were half as likely to test positive for opioids in states that had implemented medical marijuana laws (MMLs) as in states that had not.

“Among 21-to-40-year-old deceased drivers, crashing in states with an operational MML was associated with lower odds of testing positive for opioids than crashing in MML states before these laws were operational,” the researchers write. “Although we found a significant association only among drivers aged 21 to 40 years, the age specificity of this finding coheres with what we know about MMLs: a minimum age requirement restricts access to medical marijuana for most patients younger than 21 years, and most surveyed medical marijuana patients are younger than 45 years.”

The fact that a driver tested positive for opioids does not necessarily mean the painkillers he took contributed to the crash, so it is not safe to draw any conclusions about medical marijuana’s impact on traffic safety from this study. But the FARS data are an indirect way of measuring the extent of opioid consumption in a given state. Kim et al. note that “severe or chronic pain is among the most common indications cited by medical marijuana patients.” It therefore makes sense that opioid use would decline (or rise less) in states that recognize cannabis as a medicine.

Source: http://www.forbes.com/sites/jacobsullum/2016/09/22/medical-marijuana-seems-to-reduce-deaths-from-pharmaceuticals/#1a6c82b7396e

Tags: , , , , ,
Posted in GrowPros Cannabis Ventures Inc., Marijuana Company of America, Medical Marijuana Stocks | Comments Off on Medical Marijuana Seems To Reduce Deaths From Pharmaceuticals $MCOA.us $GCI.ca

« Older Entries
Newer Entries »